Month: November 2018

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for treatment of SCD

Modus Therapeutics AB, a company developing innovative treatments in disease areas with high unmet medical need with a focus on sickle cell disease (SCD), announces that the FDA has accepted its sevuparin IND for the treatment of SCD. “The FDA’s decision to accept the IND application for the development of sevuparin in sickle cell disease…